key: cord-0792944-npcz4qr2
authors: Byravan, Swetha; Fardanesh, Armin; Tahir, Hasan; Moorthy, Arumugam
title: Emerging COVID‐19 vaccines: A rheumatology perspective
date: 2021-02-01
journal: Int J Rheum Dis
DOI: 10.1111/1756-185x.14048
sha: 5cad98f335951a1bdad13830939af3314cf029e8
doc_id: 792944
cord_uid: npcz4qr2

nan

The coronavirus disease 2019 (COVID-19) pandemic gripped the world unexpectedly and little was known about the virus or its effects on various cohorts of patients. In the first wave, rheumatology patients on immunosuppressive agents were asked to shield or self-isolate because they were deemed highly clinically vulnerable.

As evidence emerged, it became apparent that most of our patients were not adversely affected with their disease management and so it gradually returned to normal. 1 Nevertheless, in light of the second wave much uncertainty remains. In this regard, the COVID-19 vaccine is eagerly anticipated to be one of the solutions to the pandemic. Emergence of several potential vaccines has been the topic of discussion in recent weeks. In this Editorial we explore the emerging vaccines and the perception, anxieties, and concerns around them from a rheumatology perspective.

COVID-19 vaccines are being developed by various pharmaceutical companies but there are three that seem to be the most promising. Pfizer/BioNTechs COVID-19 vaccine is an RNA vaccine, which is reported to be 95% effective against COVID-19 and is currently in phase 3 of its trials with over 43 000 participants; 41% of global and 45% of US participants are between 56 and 85 years, and 42% of the overall study population have a diverse ethnic background including Asian, Black, Hispanic, and Native American. Most participants have received a second dose as part of a two-dose regimen, but the details of this regimen have not been released. 2 Moderna, has also developed an RNA-based vaccine, which is up to 94.5% effective when given over two doses on days 1 and 29. 3 The clinical trial cohort includes over 30 000 participants including 7000 over 65 years of age and 5000 participants under 65 years of age with high-risk chronic diseases. AstraZeneca has produced a slightly different COVID-19 vaccine consisting of a viral vector, which is 90% effective when using one of its vaccination regimens consisting of giving a half dose initially then a full dose 1 month later. The trial population is slightly smaller than the others with over 23 000 participants and it is being conducted in the UK, Brazil and South Africa. The cohort consists of participants who are healthy and have medically stable chronic diseases. 4 At the time of writing this editorial (November 2020), the results of the phase 3 trials of these three vaccines are yet to be published and peer-reviewed, therefore available data so far are limited to press-releases.

Efficacy and safety of these emerging vaccines in the rheumatology population are unknown. It is unclear in the trials which chronic disease patient groups were included or if they were on immunosuppressive therapy. Published phase 1/2 trial data included healthy patients between the ages of 18 and 55 years, patient demographics for phase 3 trials have not been released. However, as none of these vaccines are live attenuated it is assumed that they are safe to be taken by patients on immunosuppressive treatment. The main resistance we envisage with some of the rheumatology patients in taking the vaccine is likely to be their perception rather than scientific reasoning. The RNA vaccine is the first of its kind and understandably we are all apprehensive, as little is known about the long-term side effects of this novel vaccine. So far, none of the three pharmaceutical companies has reported any serious short-term adverse effects.

The most common side effects have been fatigue and headache, similar to the influenza vaccine. 2, 3 The relationship between vaccination uptake and perception is complex. The measles, mumps, and rubella (MMR) controversy in 1998 demonstrates how MMR vaccine uptake fell in subsequent years and the efforts of health authorities to rebuild public trust.

Knowledge is power, and educating parents on the correct information was key after the MMR controversy. Milward describes certain features that affect public perception of health messages, which include the relevance of information to everyday life, its relation to other perceived risks, and the extent to which the source of information is trusted. 5 Information sourced from informal sources on the internet, social media, and print media will have a potential negative impact. Rheumatology patients are eager to have more information regarding the COVID-19 vaccine so that they can make an informed decision about their long-term disease management.

Reflecting on times when vaccines have been introduced or publicized, we can appreciate how the distribution of data regarding their safety and use is imperative to enable rational patient decisions.

There are other factors that influence patients' health decisions on a personal level, which include cultural norms, and religious, educational, and philosophical views, which can all influence attitudes to vaccinations. 6 Many patients also rely on the advice and opinion of their healthcare professional and so disseminating accurate information is vital.

The concept of vaccination is based on herd immunity where most people in a population have immunity against an infection either directly by previous infection or indirectly via a vaccine to reduce the risk of transmission to those who lack immunity. 7 The proportion of people that need to be vaccinated to achieve herd immunity depends on the infection, for example for measles it is 95%, for polio it is 80%. 8 Nevertheless, it is usually most of the population that needs to be vaccinated to protect those who cannot be | 145 EDITORIAL vaccinated. The level to achieve herd immunity against COVID-19 is unknown, but until it is achieved patients must strictly adhere to the advice from the Government to protect themselves and the community. Indeed, one of our main concerns is that rheumatology patients may become complacent after taking the vaccine. Although the full efficacy of the vaccine will only be determined with mass vaccination, it does not necessarily confer complete immunity. It is imperative that we stress to our rheumatology patients that they should continue to take protective measures.

Lockdown, social distancing, and increased hand washing have gone some way in reducing the incidence of the virus below a reproduction rate of 1, but this will not be enough to eliminate the virus. History has demonstrated recurrent epidemic cycles with other contagious infections such as measles, mumps, and smallpox in the pre-vaccine period. 9 It is unknown whether the COVID-19 immunization program will achieve disease elimination or eradication. Elimination is the absence of sustained endemic community transmission in a geographical area and eradication is the reduction of cases to zero globally. Another factor contributing to eradication vs elimination is how long a patient will retain im- vaccines are two dose regimens the second dose will hopefully cover those patients who did not produce a strong immune response with the first dose.

A concern among clinicians is whether immunosuppressed patients will mount a sufficient immune response to the vaccine. The However, there are few data from practical use because the vaccine was used for "compassionate use", so only a small number of patients who were considered to be high risk were given the vaccine in sub-Saharan Africa. In terms of adverse effects, the main side effects were flu-like symptoms in the first 4 days following vaccination, which is like live virus vaccines. The influenza vaccine is an annual inactivated vaccine recommended to certain groups of vulnerable people including those who are immunocompromised. In the rheumatology population it seems the vaccine mounts a good immune response and reduces the risk of respiratory morbidity and mortality. 14 Apart from live vaccines, all other vaccines are currently safe to use in the rheumatology population and it seems that they mount a sufficient response to provide immunity. This creates an optimistic outlook for the new COVID-19 vaccine and its anticipated therapeutic effect.

The need for revaccination is yet to be determined. The genome of the current SARS-CoV-2 virus strongly resembles its predecessor SARS-CoV, with novel glycosylation sites secondary to antigenic divergence. Therefore, although a vaccine now may confer protection against the current SARS-CoV-2 strain, it begs the question if the vaccine will be effective against evolving genomics in the coming years. There is yet the possibility that because of antigenic drift, further modifications in the vaccine maybe necessary to protect against novel coronaviruses. 15

The COVID-19 vaccine brings hope to what has seemed quite a bleak and uncertain year. Vaccines provide a long-term solution to the pandemic; however, before we recommend these vaccines to our rheumatology patients, we must have adequate information about their efficacy and safety in the immunosuppressed population. Patients are both eager and anxious to receive the COVID-19 vaccine. Therefore, as healthcare professionals we need to be armed with the correct information before counseling our patients.

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot

Pfizer and Biontech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints

Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Vaccinating Britain: Mass Vaccination and the Public Since the Second World War

Understanding vaccine acceptance and demand-and ways to increase them

Herd immunity: history, theory, practice

World Health Organisation. Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19

Elimination of COVID-19: what would it look like and is it possible?

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

SARS-CoV-2 reinfection in two patients who have recovered from COVID-19

Next-generation vaccine platforms for COVID-19

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs

Emergence and Reemergence of Severe Acute Respiratory Syndrome (SARS) Coronaviruses. Coronavirus Disease